(MASI) Masimo - Overview
Exchange: NASDAQ •
Country: United States •
Currency: USD •
Type: Common Stock •
ISIN: US5747951003
Stock: Oximetry, Monitoring, Capnography, Automation, Therapy
Total Rating 30
Risk 92
Buy Signal -0.53
EPS (Earnings per Share)
Revenue
| Risk 5d forecast | |
|---|---|
| Volatility | 36.5% |
| Relative Tail Risk | -6.46% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | -0.50 |
| Alpha | -39.92 |
| Character TTM | |
|---|---|
| Beta | 1.215 |
| Beta Downside | 1.434 |
| Drawdowns 3y | |
|---|---|
| Max DD | 60.95% |
| CAGR/Max DD | -0.09 |
Description: MASI Masimo January 06, 2026
Masimo Corporation (NASDAQ:MASI) designs, manufactures, and sells a broad portfolio of patient-monitoring and connectivity solutions, ranging from its flagship SET pulse-oximetry and Rainbow SET multi-parameter platforms to hospital-automation software (e.g., Patient SafetyNet, Iris) and consumer-focused wellness devices sold online.
Key recent metrics (FY 2024, company-released) show revenue of roughly $2.2 billion, a year-over-year increase of about 12 % driven largely by growth in remote-patient-monitoring (RPM) and hospital-automation contracts; operating margin expanded to 14 % as software-licensing revenue scaled with lower variable costs. The market for non-invasive monitoring is expanding at a compound annual growth rate of ~8 % (industry estimates), supported by an aging U.S. population, increasing demand for telehealth, and favorable reimbursement trends for RPM under Medicare.
For a deeper, data-driven view of MASI’s valuation dynamics, you might explore the analyst tools on ValueRay.
Piotroski VR‑10 (Strict, 0-10) 5.0
| Net Income: -569.4m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.10 > 0.02 and ΔFCF/TA 5.60 > 1.0 |
| NWC/Revenue: 39.57% < 20% (prev 36.98%; Δ 2.59% < -1%) |
| CFO/TA 0.11 > 3% & CFO 207.8m > Net Income -569.4m |
| Net Debt/EBITDA: error (EBITDA <= 0) |
| Current Ratio: 2.84 > 1.5 & < 3 |
| Outstanding Shares: last quarter (54.4m) vs 12m ago 0.18% < -2% |
| Gross Margin: 54.96% > 18% (prev 0.54%; Δ 5442 % > 0.5%) |
| Asset Turnover: 69.93% > 50% (prev 56.25%; Δ 13.67% > 0%) |
| Interest Coverage Ratio: -3.55 > 6 (EBITDA TTM -71.2m / Interest Expense TTM 35.8m) |
Altman Z'' 5.69
| A: 0.37 (Total Current Assets 1.05b - Total Current Liabilities 369.7m) / Total Assets 1.82b |
| B: 0.70 (Retained Earnings 1.27b / Total Assets 1.82b) |
| C: -0.05 (EBIT TTM -127.2m / Avg Total Assets 2.45b) |
| D: 1.25 (Book Value of Equity 1.26b / Total Liabilities 1.01b) |
| Altman-Z'' Score: 5.69 = AAA |
Beneish M -3.91
| DSRI: 0.81 (Receivables 355.9m/444.6m, Revenue 1.72b/1.74b) |
| GMI: 0.98 (GM 54.96% / 54.10%) |
| AQI: 0.55 (AQ_t 0.23 / AQ_t-1 0.42) |
| SGI: 0.99 (Revenue 1.72b / 1.74b) |
| TATA: -0.43 (NI -569.4m - CFO 207.8m) / TA 1.82b) |
| Beneish M-Score: -3.91 (Cap -4..+1) = AAA |
What is the price of MASI shares?
As of February 07, 2026, the stock is trading at USD 139.15 with a total of 558,924 shares traded.
Over the past week, the price has changed by +1.33%, over one month by +1.87%, over three months by -3.26% and over the past year by -22.70%.
Over the past week, the price has changed by +1.33%, over one month by +1.87%, over three months by -3.26% and over the past year by -22.70%.
Is MASI a buy, sell or hold?
Masimo has received a consensus analysts rating of 4.11.
Therefore, it is recommended to buy MASI.
- StrongBuy: 4
- Buy: 2
- Hold: 3
- Sell: 0
- StrongSell: 0
What are the forecasts/targets for the MASI price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 183.8 | 32.1% |
| Analysts Target Price | 183.8 | 32.1% |
| ValueRay Target Price | 131 | -5.8% |
MASI Fundamental Data Overview February 03, 2026
P/E Forward = 40.0
P/S = 3.3806
P/B = 9.1062
P/EG = 4.7295
Revenue TTM = 1.72b USD
EBIT TTM = -127.2m USD
EBITDA TTM = -71.2m USD
Long Term Debt = 559.1m USD (from longTermDebt, last quarter)
Short Term Debt = 7.70m USD (from shortTermDebt, last quarter)
Debt = 586.2m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 271.5m USD (from netDebt column, last quarter)
Enterprise Value = 7.65b USD (7.38b + Debt 586.2m - CCE 314.7m)
Interest Coverage Ratio = -3.55 (Ebit TTM -127.2m / Interest Expense TTM 35.8m)
EV/FCF = 40.27x (Enterprise Value 7.65b / FCF TTM 189.9m)
FCF Yield = 2.48% (FCF TTM 189.9m / Enterprise Value 7.65b)
FCF Margin = 11.07% (FCF TTM 189.9m / Revenue TTM 1.72b)
Net Margin = -33.20% (Net Income TTM -569.4m / Revenue TTM 1.72b)
Gross Margin = 54.96% ((Revenue TTM 1.72b - Cost of Revenue TTM 772.5m) / Revenue TTM)
Gross Margin QoQ = 62.07% (prev 62.90%)
Tobins Q-Ratio = 4.21 (Enterprise Value 7.65b / Total Assets 1.82b)
Interest Expense / Debt = 1.50% (Interest Expense 8.80m / Debt 586.2m)
Taxrate = 28.30% (21.2m / 74.9m)
NOPAT = -91.2m (EBIT -127.2m * (1 - 28.30%)) [loss with tax shield]
Current Ratio = 2.84 (Total Current Assets 1.05b / Total Current Liabilities 369.7m)
Debt / Equity = 0.72 (Debt 586.2m / totalStockholderEquity, last quarter 810.0m)
Debt / EBITDA = -3.81 (negative EBITDA) (Net Debt 271.5m / EBITDA -71.2m)
Debt / FCF = 1.43 (Net Debt 271.5m / FCF TTM 189.9m)
Total Stockholder Equity = 962.8m (last 4 quarters mean from totalStockholderEquity)
RoA = -23.22% (Net Income -569.4m / Total Assets 1.82b)
RoE = -59.14% (Net Income TTM -569.4m / Total Stockholder Equity 962.8m)
RoCE = -8.36% (EBIT -127.2m / Capital Employed (Equity 962.8m + L.T.Debt 559.1m))
RoIC = -5.66% (negative operating profit) (NOPAT -91.2m / Invested Capital 1.61b)
WACC = 9.70% (E(7.38b)/V(7.96b) * Re(10.39%) + D(586.2m)/V(7.96b) * Rd(1.50%) * (1-Tc(0.28)))
Discount Rate = 10.39% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 33.33 | Cagr: 0.65%
[DCF Debug] Terminal Value 62.93% ; FCFF base≈173.8m ; Y1≈114.1m ; Y5≈52.0m
Fair Price DCF = 9.60 (EV 787.1m - Net Debt 271.5m = Equity 515.6m / Shares 53.7m; r=9.70% [WACC]; 5y FCF grow -40.0% → 2.90% )
EPS Correlation: -27.52 | EPS CAGR: -48.16% | SUE: -4.0 | # QB: 0
Revenue Correlation: -10.70 | Revenue CAGR: 3.41% | SUE: 0.07 | # QB: 0
EPS next Quarter (2026-03-31): EPS=1.43 | Chg30d=+0.005 | Revisions Net=+1 | Analysts=6
EPS next Year (2026-12-31): EPS=5.90 | Chg30d=+0.002 | Revisions Net=+2 | Growth EPS=+6.2% | Growth Revenue=+6.6%
P/S = 3.3806
P/B = 9.1062
P/EG = 4.7295
Revenue TTM = 1.72b USD
EBIT TTM = -127.2m USD
EBITDA TTM = -71.2m USD
Long Term Debt = 559.1m USD (from longTermDebt, last quarter)
Short Term Debt = 7.70m USD (from shortTermDebt, last quarter)
Debt = 586.2m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 271.5m USD (from netDebt column, last quarter)
Enterprise Value = 7.65b USD (7.38b + Debt 586.2m - CCE 314.7m)
Interest Coverage Ratio = -3.55 (Ebit TTM -127.2m / Interest Expense TTM 35.8m)
EV/FCF = 40.27x (Enterprise Value 7.65b / FCF TTM 189.9m)
FCF Yield = 2.48% (FCF TTM 189.9m / Enterprise Value 7.65b)
FCF Margin = 11.07% (FCF TTM 189.9m / Revenue TTM 1.72b)
Net Margin = -33.20% (Net Income TTM -569.4m / Revenue TTM 1.72b)
Gross Margin = 54.96% ((Revenue TTM 1.72b - Cost of Revenue TTM 772.5m) / Revenue TTM)
Gross Margin QoQ = 62.07% (prev 62.90%)
Tobins Q-Ratio = 4.21 (Enterprise Value 7.65b / Total Assets 1.82b)
Interest Expense / Debt = 1.50% (Interest Expense 8.80m / Debt 586.2m)
Taxrate = 28.30% (21.2m / 74.9m)
NOPAT = -91.2m (EBIT -127.2m * (1 - 28.30%)) [loss with tax shield]
Current Ratio = 2.84 (Total Current Assets 1.05b / Total Current Liabilities 369.7m)
Debt / Equity = 0.72 (Debt 586.2m / totalStockholderEquity, last quarter 810.0m)
Debt / EBITDA = -3.81 (negative EBITDA) (Net Debt 271.5m / EBITDA -71.2m)
Debt / FCF = 1.43 (Net Debt 271.5m / FCF TTM 189.9m)
Total Stockholder Equity = 962.8m (last 4 quarters mean from totalStockholderEquity)
RoA = -23.22% (Net Income -569.4m / Total Assets 1.82b)
RoE = -59.14% (Net Income TTM -569.4m / Total Stockholder Equity 962.8m)
RoCE = -8.36% (EBIT -127.2m / Capital Employed (Equity 962.8m + L.T.Debt 559.1m))
RoIC = -5.66% (negative operating profit) (NOPAT -91.2m / Invested Capital 1.61b)
WACC = 9.70% (E(7.38b)/V(7.96b) * Re(10.39%) + D(586.2m)/V(7.96b) * Rd(1.50%) * (1-Tc(0.28)))
Discount Rate = 10.39% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 33.33 | Cagr: 0.65%
[DCF Debug] Terminal Value 62.93% ; FCFF base≈173.8m ; Y1≈114.1m ; Y5≈52.0m
Fair Price DCF = 9.60 (EV 787.1m - Net Debt 271.5m = Equity 515.6m / Shares 53.7m; r=9.70% [WACC]; 5y FCF grow -40.0% → 2.90% )
EPS Correlation: -27.52 | EPS CAGR: -48.16% | SUE: -4.0 | # QB: 0
Revenue Correlation: -10.70 | Revenue CAGR: 3.41% | SUE: 0.07 | # QB: 0
EPS next Quarter (2026-03-31): EPS=1.43 | Chg30d=+0.005 | Revisions Net=+1 | Analysts=6
EPS next Year (2026-12-31): EPS=5.90 | Chg30d=+0.002 | Revisions Net=+2 | Growth EPS=+6.2% | Growth Revenue=+6.6%